Impact of Gastrointestinal Contents on Absorption
The presence of food in the digestive tract has a multifaceted effect on drug pharmacokinetics. On the one hand, food creates a physical mechanical obstacle, blocking full contact between drug molecules and the absorptive surface of the mucosa. Furthermore, certain nutrients can enhance peristalsis, shortening the time the drug remains in the optimal absorption zone. On the other hand, digestion is accompanied by a robust increase in blood flow within the intestinal wall, which may instead intensify drug penetration into the systemic circulation.
A fundamental pharmacokinetic rule states that food delays gastric emptying. This causes the drug to reach the small intestine—the primary site of absorption—later, thereby reducing the rate of absorption for most medications.
A major exception to this rule is highly lipophilic compounds. Dietary fats are potent stimulators of bile release. Bile acids provide effective emulsification and solubilization of fat-soluble molecules. Consequently, the absorption of spironolactone (Spironolactonum), griseofulvin (Griseofulvinum), and fat-soluble vitamins increases significantly when taken with high-fat meals.
Chemical and Metabolic Interactions
Food components can participate in direct physicochemical reactions with active drug molecules, altering their bioavailability. A classic example is the interaction of calcium ions, abundant in dairy products, with tetracycline antibiotics. This forms stable, insoluble chelate complexes that pass through the GI tract without being absorbed. Strong tea produces a similar precipitating effect: tannins bind plant alkaloids such as papaverine (Papaverinum) and codeine (Codeinum).
Metabolic Interaction (The "Grapefruit Juice Effect") A clinically significant interaction occurs at the level of enterocyte enzyme systems. Citrus fruits (grapefruit, pomelo, lime) contain specific compounds known as furanocoumarins (e.g., dihydroxybergamottin).
- Furanocoumarins act as irreversible inhibitors of the intestinal cytochrome P450 isozyme — CYP3A4.
- As a result, presystemic metabolism of substrate drugs directly in the intestinal wall is suppressed.
- The bioavailability and plasma concentrations of drugs (such as nifedipine — Nifedipinum, cyclosporine — Cyclosporinum, and statins) increase sharply and unpredictably.
- The risk of severe toxicity and overdose multiplies, making these beverages strictly contraindicated during such therapies.
Role of Gastric and Intestinal Motility
The rate of gastric emptying is a critical factor determining how rapidly a drug reaches the duodenum. Physiologically, liquids leave the stomach the fastest. Solid food is retained longer, with the evacuation rate depending on chemical composition (carbohydrates leave faster than proteins, and fats leave the slowest). High caloric density, extreme meal temperatures (very hot or ice-cold), and high chyme acidity slow down this process. Conversely, large food particles stimulate mechanoreceptors and accelerate emptying.
Pharmacological Regulation of Motility:
- Acceleration: Prokinetics (metoclopramide) and macrolides stimulate rapid delivery of chyme to the intestine. This leads to accelerated absorption of weak bases (propranolol).
- Deceleration: Muscarinic antagonists relax smooth muscle, delaying the onset of the therapeutic effect.
Peristalsis is particularly important for slowly absorbed drugs, such as iron preparations or cardiac glycosides. When prokinetics are administered, chyme moves too quickly, preventing adequate drug absorption and reducing bioavailability. Conversely, the inhibition of peristalsis by atropine (Atropinum) prolongs transit time, extends mucosal contact, and can lead to complete absorption of even toxic doses of digoxin.
Microbiome and Drug Interactions During Absorption
The normal GI microflora actively participates in drug metabolism even before systemic absorption occurs. A striking clinical example is digoxin (Digoxinum). In a healthy gut, the bacterium Eubacterium lentum inactivates about 40% of the ingested dose of this glycoside. If a patient is prescribed a course of antibiotics, the flora is suppressed, intra-luminal digoxin metabolism ceases, and the absorption of the active fraction rises sharply. Given the narrow therapeutic index of digoxin, this poses a severe risk of glycoside toxicity.
Drug-Drug Interactions:
- Adsorbents: Activated charcoal (Carbo activatus) nonspecifically binds molecules to its surface, suppressing the absorption of any co-administered drugs.
- Antacids: Aluminum, calcium, and magnesium preparations form non-absorbable chelates with fluoroquinolones. Additionally, by increasing gastric pH, antacids impair the ionization and absorption of weak acids while enhancing the absorption of weak bases.
- Transporter Systems: Blockade of P-glycoprotein (responsible for pumping xenobiotics back into the lumen) promotes abnormal drug accumulation.
To avoid conflicts during absorption, a minimum interval of 2 hours is required between interacting agents.